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1. INTRODUCTION 
1.1 Venous thromboembolism 
Deep vein thrombosis (DVT) is the formation of a blood cloth in the deep veins. DVT usually 
affects the large veins of the leg or thigh, but can also occur in other parts of the body. 
Pulmonary embolism (PE) occurs when a blood clot dislodges from its original site and 
embolize to the arterial blood supply of the lungs. DVT and PE are collectively referred to as 
venous thromboembolism (VTE). VTE is a relatively common disorder that affects 1-2 per 
1000 individuals each year, and the incidence increases markedly with age, from about 1 per 
10 000 in young adults, to 1 per 100 in elderly [1]. In most studies, the incidence of clinically 
diagnosed DVT is reported to be approximately twice that of PE [2]. However, DVT and PE 
share the same underlying pathology and the two conditions are often presented at the same 
time. Among subjects with acute DVT, concurrent, clinically silent PE is found in 30-50 % 
[3]. Likewise, among those with acute PE, clinically silent DVT is present in about 80 % of 
the subjects [4].  
VTE is the third most common life-threatening cardiovascular disease [5], and is a 
major cause of morbidity and mortality. The one-week survival rate after a PE is 
approximately 70 %, and almost 25 % of all PE-cases essentially present as sudden death [6]. 
VTE is associated with short term complications such as local extension of the disease, further 
embolization and recurrence of the disease within weeks to months of the initial episode. 
Serious long-term complications includes the post-thrombotic syndrome, venous 
insufficiency, pulmonary hypertension and late risk of recurrent VTE [4,7].   
In 1859, the brilliant pathologist Rudolph Virchow concluded that (i) blood stasis, (ii) 
hypercoagulability and (iii) changes in the vessel wall were the major factors responsible for 
the development of VTE [8]. The triad still applies, and if one examines the commonly 
accepted risk factors for VTE, nearly all fall into one or more of these categories. Today, VTE 
 6
is recognized as a complex, multifactor disease involving both environmental exposures as 
well as genetic and environmental interactions. Acquired risk factors include advancing age, 
obesity, surgery, trauma, hospitalization, acute medical conditions, malignancy, 
immobilization, pregnancy, use of estrogens and the lupus anticoagulant [9,10]. Inherited 
thrombophilic factors that predispose to VTE include factor V Leiden mutation, prothrombin 
20210A mutation, elevated levels of factor VIII, activated protein C (APC) resistance and 
deficiencies of antithrombin, protein C or protein S [9].  
Advanced age is a well-accepted, independent risk factor for VTE [1]. The 
Longitudinal Investigation of Thromboembolism Etiology (LITE) study found that age 
independently increased the risk of VTE by approximately 2-fold per decade, and that 
subjects older than 75 years had a 15-fold increased risk compared to those aged 45-54 years 
[11]. In patients hospitalized for VTE there was an exponential relationship between VTE 
incidence and age, with a 2-fold increase per decade [12]. Although it is not certain why risk 
is dependent on age, it has been suggested that it might be related to a combination of factors 
such as decreased mobility and degenerative vascular changes [13].  
During the recent years, growing evidence for obesity as a risk factor for VTE has 
been presented. Data from the Physicians’ Health Study [5] indicated that BMI is a strong 
predictor for VTE. Furthermore, BMI ≥ 30 kg/m2 was associated with a 2 to 3-fold increased 
risk of VTE [11] and PE [14] in prospective studies. A prospective study among middle-aged 
men identified waist circumference as an independent predictor for VTE [15], and increased 
waist circumference and waist hip ratio have been reported in case-control studies among 
patients with unprovoked VTE [16] and recurrent VTE [17]. 
Previous studies have reported that hospitalized patients have substantially increased 
risk of VTE compared to non-hospitalized patients [10,18]. Furthermore, PE accounts for 
approximately 10 % of all in-hospital deaths [19]. Major surgery is a well recognized risk 
 7
factor for VTE, and surgery within the last 45-90 days confers a 4-22 fold increased risk of 
VTE [20]. Active malignant disease has been shown to be an independent risk factor for VTE 
[10,21], and the incidence of VTE in cancer populations has been reported to be 5-fold higher 
than that of the general population [22]. Overall, 18–29% of all VTE events in the community 
have been shown to be associated with cancer [23-25]. Several other clinical conditions are 
associated with increased risk of VTE. The incidence of subclinical DVT in patients 
hospitalized with acute medical conditions such as acute MI, stroke, heart failure and acute 
infections varies from 20-50 % [26,27]. 
Compared to non-pregnant subjects the risk of VTE is estimated to be 4 to 5-fold  
increased during pregnancy [28,29], and approximately 20-fold increased postpartum [28]. 
Fatal PE remains the most common cause of maternal mortality in many western countries 
[30]. Estrogen therapy, such as oral contraceptives and hormone replacement therapy, is also 
associated with increased risk of VTE. The absolute risk of VTE is 2 to 4-fold higher in 
women taking second-generation oral contraceptives, and 3 to 8-fold higher in women taking 
third-generation oral contraceptives [31]. In a meta-analysis of 12 studies the relative risk of 
VTE was 2.1 among current users of hormone replacement therapy, and the risk was highest 
(RR=3.5) during the first year of use [32]. 
  Inherited thrombophilia is a genetically determined tendency to form thrombosis. The 
most common prothrombotic abnormalities include APC resistance (e.g. factor V Leiden 
mutation), prothrombin G20210A mutation, deficiencies of antithrombin, protein C or protein 
S and elevated levels of factors VIII, IX and XI [33]. APC resistance is caused by a single 
point mutation in the factor V gene which leads to inefficient cleavage of factor V. The 
mutation is present in 3-5 % of the Caucasian population, and is associated with a 7-fold 
increased risk of DVT in heterozygous individuals [34] and 80-fold increased risk in 
homozygous individuals [35]. Thrombin, the activated form of prothrombin, plays a key role 
 8
in the conversion of fibrinogen to fibrin and platelet activation. The overall prevalence of the 
prothrombin G20210A mutation, a one nucleotide change in the prothrombin gene, is about 2 
% in the healthy European population [36]. The mutation is associated with an approximately 
3-fold increased risk of VTE [37], dependent on the presence of additional inherited or 
acquired risk factors [38]. Antithrombin deficiency is a rare genetic defect found in 1-2 % of 
VTE patients, and is associated with a 10 to 20-fold increased risk of VTE [39,40]. 
Heterozygous deficiency of protein C is present in 2-5 % of VTE patients and 0.3-0.5 % of 
healthy controls, suggesting a 10-fold increased risk of VTE [40]. The prevalence of protein S 
deficiency in the general population is unacquainted [41], but family studies have suggested 
that the risk of VTE is similar to that in patients with protein C deficiency or APC-resistance 
[41-43].  
Despite the identification of several inherited and acquired risk factors associated with 
VTE, still 30-50 % of the VTE-cases are unprovoked, i.e. they occur in the absence of 
obvious predisposing factors [2,44]. Clearly, there are still unrecognized environmental and/or 
genetic risk factors for VTE. Consequently, identification of new risk factors is essential in 
order to enhance the understanding of pathophysiological mechanisms of VTE, and to 
optimize individual risk stratification and treatment of the disease.  
 
 
1.2 Possible link between arterial and venous thrombosis 
Traditionally, arterial thromboembolic disease (acute myocardial infarction (MI), stroke and 
peripheral artery disease) and VTE has been considered as separate diseases, with different 
pathology, epidemiology and treatments. Platelet-fibrin haemostatic plugs are the 
pathophysiological basis for both arterial and venous thrombosis, but the different clinical 
presentations of the diseases, and the obvious anatomical differences in the composition of the 
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thrombi, have contributed to the concept of these conditions as distinct entities. Arterial 
cardiovascular disease is mainly associated with atherosclerosis. Arterial thrombi tend to 
occur at atherosclerotic plaque lesions, where share rates are high, and are platelet rich ‘white 
thrombi’. In contrast, thrombi that form in the slow-flowing venous system are rich in red 
cells and fibrin, and are referred to as ‘red thrombi’. Compared to the detailed knowledge of 
arterial thrombosis, where mechanisms are well understood even to the molecular level, our 
current understanding of the pathophysiological mechanisms of VTE is limited. However, 
development of venous thrombi has traditionally been thought to arise from reduced blood 
flow and states of hypercoagulability rather than atherosclerosis.  
Recently, the concept of this clear-cut distinction between arterial and venous 
thrombosis has been challenged. In 2003, Prandoni et al. reported a higher frequency of 
carotid plaques in patients with unprovoked DVT compared to hospitalized controls [45]. This 
study certainly re-opened the case of a potential link between arterial and venous thrombosis. 
However, later prospective studies have shown diverging results regarding subclinical 
atherosclerosis and VTE. A significant relation between carotid intima media thickness and 
VTE was found in a prospective cohort of 13 081 middle-aged subjects, but the association 
disappeared when adjusting for atherosclerotic risk factors [46]. Another study in elderly 
subjects failed to show any association between subclinical atherosclerosis and VTE [47]. 
Studies of the association between arterial thromboembolic disease and VTE showed that 
subjects with VTE had increased risk of arterial events compared to the general population 
[48,49], and that the risk of arterial events was higher in subjects with unprovoked VTE 
compared to subjects with provoked VTE [50,51]. Another study showed that a first arterial 
event was associated with subsequent development of VTE [46]. Recently, a large Danish 
cohort study reported that the long-term incidence of cardiovascular disease was substantially 
increased in patients with VTE compared to population controls [52]. However, the latter 
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study did not investigate potential common risk factors, and thus adjustments could not be 
made for factors such as BMI and other arterial cardiovascular risk factors. 
In summary, increasing evidence supports the concept of a link between arterial and 
venous thrombosis. However, the studies show somewhat diverging results. In addition, some 
of the studies have considerable methodological limitations, as most of the studies were 
carried out in specific populations such as middle-aged [46] or elderly [47], and the majority 
used hospitalized controls rather than healthy subjects [45,50,51]. Thus, further research, 
preferably prospective, population-based studies, are required to establish the magnitude and 
possible causes of an association between arterial thromboembolic disease and VTE. It is also 
important to consider the associations of VTE with three stages of the development of arterial 
cardiovascular disease; that is risk factors, subclinical disease, and clinical disease.  
 
 
1.3 Cardiovascular risk factors and risk of venous thromboembolism 
In 2006, Angelli and Becattini [53] stated that ‘the sharing of common risk factors would 
certainly reinforce the link between atherosclerosis and VTE and could lead to the view that 
arterial and venous thrombosis are different presentations of the same disease’. A recent meta-
analysis, based on mainly case-control studies and selected prospective studies with verified 
endpoints, concluded that cardiovascular risk factors such as obesity, hypertension, diabetes 
mellitus and low HDL-cholesterol were significantly associated with VTE [54]. However, 
prospective studies on relation between traditional cardiovascular risk factors and VTE show 
diverging results. In the Nurses’ Health Study, a prospective cohort of 112 822 female nurses 
aged 30-55, obesity, cigarette smoking and hypertension, but not diabetes or elevated 
cholesterol, were independent predictors for PE [14]. In the Physicians’ Health Study [5], a 
prospective cohort of 18 622 male physicians followed for over 20 years, only BMI and 
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height were identified as independent risk factors for VTE, whereas smoking and abdominal 
obesity were predictors for VTE in another study on 855 Swedish middle-aged men [15]. In 
the LITE-study, a prospective cohort of 19 293 men and women aged 45 or older, obesity and 
diabetes, but not cigarette smoking, hypertension and dyslipidemia, showed independent 
association to VTE [11]. In the Copenhagen City Heart Study, investigating 9 238 men and 
women, total cholesterol, HDL-cholesterol (inverse), diabetes and smoking were associated 
with VTE [55] in crude analysis, but further adjustments for potential confounders such as 
age, gender or BMI were not undertaken, nor were the results presented in multivariable 
analysis.  
The observed inconsistency between these studies may to some extent rely on 
differences in study design, presentation of data, outcome verification and study population. 
In general, the results of case-control studies are affected by the selection of cases, eligible 
control group and to what extent the disease state and other confounders affect the predictor 
variable. Some of the prospective studies presented crude data only [55], while others had 
made adjustments for various potential confounders [11]. Outcome detection and verification 
differed as some of the studies relied on self-reported outcome [5,11,14] whereas others had 
objectively detected VTE-events [55]. In addition, several studies were performed in highly 
selected population groups such as female nurses [14], male physicians [5] middle-aged men 
[56] and postmenopausal women [57]. Thus, to establish the true associations between 
various cardiovascular risk factors and VTE, these hypotheses should be further investigated 
in large, prospective, cohort studies of general populations, preferably with objectively 
detected and validated outcome measures.  
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1.4 Metabolic syndrome and risk of venous thromboembolism 
The metabolic syndrome is a cluster of cardiovascular risk factors [58]. According to 
guidelines from the National Cholesterol Education Program-Adult Treatment Panel III 
(NCEP-ATPIII) the presence of 3 of 5 factors is required to establish the diagnosis [59]. 
These factors include insulin resistance, abdominal obesity, high triglyceride levels, low 
HDL-cholesterol levels and hypertension [59]. Although the prevalence of the components of 
the metabolic syndrome is increased in obesity [60], it is important to notice that not all obese 
subjects develop the metabolic syndrome, and even non-obese individuals can carry the 
syndrome.  
The metabolic syndrome is a cluster of interrelated risk factors of metabolic origin, 
that appear to directly promote the development of atherosclerotic cardiovascular disease and 
diabetes mellitus [59,61]. Epidemiological studies have shown that the metabolic syndrome is 
associated with increased risk of coronary heart disease (CHD), cardiovascular disease 
(CVD), and overall mortality [62,63]. Several factors contribute to cause a hypercoagulable 
state in patients with the metabolic syndrome. Adipose tissue is a remarkable endocrine organ 
that produces prothrombotic and inflammatory molecules [64], and fibrinolytic activity and 
function are impaired in subjects with the metabolic syndrome, mainly related to visceral 
obesity and insulin resistance [65,66]. Individuals with the metabolic syndrome exhibit 
increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) [67], and clotting factors 
VII and XIII [68]. Subjects with the metabolic syndrome usually exhibit a higher platelet 
activity than those with conventional risk factors for vascular disease [69]. Hyperinsulinemia 
and dyslipidemia have been associated with induction of endothelial dysfunction, and 
endothelial dysfunction, measured by flow mediated dilation to assess nitric oxide 
bioavailability, is commonly found in subjects with the metabolic syndrome [68]. Altogether, 
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these prothrombotic factors associated with the metabolic syndrome contribute to potentially 
increase the risk of future thrombotic events in both the arterial and venous system.  
An intriguing question to investigate is whether the metabolic syndrome, as well as its 
predefined individual components, is associated with VTE. To date, only a few studies have 
investigated this relationship. Two recent case-control studies demonstrated a two-fold higher 
prevalence of the metabolic syndrome in patients with unprovoked DVT [16] and recurrent 
VTE [17] compared to controls, whereas a prospective study of 5 522 adults with CVD or 
diabetes [70] failed to show an association between the metabolic syndrome and VTE, but 
found a higher incidence rate of VTE in patients with abdominal obesity. Differences in study 
design, eligible control groups and definitions of the metabolic syndrome could be a possible 
explanation for the observed inconsistency between these studies. Thus, the relationship 
between the metabolic syndrome and VTE should be further examined in large cohort studies.  
 
 
1.5 HDL-cholesterol and risk of venous thromboembolism  
Atherosclerosis is a chronic, progressive disease which involves the formation of lesions in 
the arteries mainly characterized by accumulation of lipids, inflammation, cell death and 
fibrosis [71]. An atherosclerotic plaque contains inflammatory and immune cells, lipids, 
extracellular matrix, vascular smooth muscle cells and acellular lipid-rich debris [72]. The 
atherosclerotic lesions typically present as asymmetric thickening of the innermost layer of 
the artery (intima), a process that begins with the formation of fatty streaks which can 
progress into mature atherosclerotic plaques (atheromas). An atheroma typically comprises a 
core of extracellular lipid droplets and foam cells surrounded by a cap of smooth muscle cells 
and collagen-rich matrix [73]. With time, the plaque can progress into a more fibrotic and 
complex lesion which eventually leads to clinical manifestation of CAD or other 
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atherosclerotic disease. A rupture or fissuring of the fibrous cap displays the prothrombotic 
material in the lesion to the blood stream, and this may trigger an acute fatal thrombosis. The 
risk of clinical events is associated with plaque morphology [74]. Lipid rich, soft plaques 
covered by a thin fibrotic cap are more prone to rupture and cause clinical events compared to 
collagen-rich, hard plaques [74].  
The protective effect of high density lipoprotein (HDL) cholesterol against CAD was 
first identified in the Tromsø Study more than three decades ago [75], and consistent findings 
in subsequent epidemiological studies have established low HDL-cholesterol as a strong risk 
factor for CAD [76,77]. HDL-cholesterol is thought to protect against CAD through both 
antiatherogenic and antithrombotic mechanisms. HDL-mediated transport of excess 
cholesterol from peripheral tissue is considered to be the main antiatherogenic function of 
HDL-cholesterol [78]. In addition, several other properties are likely to contribute to the 
atheroprotective action of HDL. Low density lipoprotein (LDL) oxidation is commonly 
considered a key factor in the initiation and progression of atherosclerosis [79]. HDL-
cholesterol protects both lipid and protein moieties of LDL from oxidation via several 
mechanisms [80-82]. HDL exerts anti-inflammatory properties by its ability to decrease the 
expression of adhesion molecules to endothelial cells and inhibit monocyte adhesion to the 
endothelium [83,84], and HDL also improves endothelial function by mechanisms such as 
stimulation of nitric oxide synthesis [85-87], inhibition of the vasoconstrictor endothelin-1, 
and stimulation of endothelial cell migration and survival [88,89]. Furthermore, HDL exerts 
several antithrombotic properties. HDL improves blood flow by increasing nitric oxide and 
prostaglandin I2 production [88]. HDL downregulates E-selectin and tissue factor [88], and 
promotes fibrinolysis by downregulating plasminogen activator inhibitor 1 (PAI-1) and 
upregulating tissue plasminogen activator [90]. Moreover, HDL attenuates platelet activation 
and aggregation [91-93], and activates the endogenous anticoagulants protein C and S [94]. In 
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epidemiological studies, HDL-cholesterol has been associated with increased plaque 
echogenicity, suggesting that high levels of HDL-cholesterol provide more stable plaques 
[95]. High levels of HDL-cholesterol has also been shown to reduce plaque growth in subjects 
with pre-existing carotid atherosclerosis [96]. 
 Several studies have suggested that high HDL-cholesterol is associated with decreased 
risk of venous thrombosis and have posed the concept that HDL-cholesterol protect against 
VTE [55-57,97-99]. Recently, a meta-analysis, including mostly case-control studies, 
concluded that low HDL-cholesterol predispose to VTE [54]. This interpretation is supported 
by the antiatherogenic and antithrombotic properties of HDL particles [88,100]. However, 
data from large cohort studies, not included in the meta-analysis due to methodological 
considerations, showed no association between HDL-cholesterol and VTE [5,14]. 
Furthermore, original data from the LITE-study showed no association between HDL-
cholesterol and VTE [11], and a recent publication presenting a more extensive examination 
of HDL-cholesterol, including a nested case-control subset of Apo-I and HDL fractions, did 
not reveal any association with VTE in the LITE-study [101].  
 
 
1.6 Platelet function and risk of venous thromboembolism 
The hemostatic system is simultaneously able to maintain the blood in a fluid state, so that it 
can circulate, and to convert the blood into an insoluble gel at sites of vascular injury. The 
hemostatic system is based on a complex interplay between platelets and coagulation proteins 
[102]. Platelets play a key role in the initiation of a blood clot. In response to vascular 
damage, platelets adhere to the vascular subendothelium via von Willebrand factor (vWF) 
bridging between subendothelial macromolecules and glycoprotein Ib receptors on the platelet 
surface [103]. Secretion of mediators including adenosine diphosphate (ADP), thrombin, 
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epinephrine and thromboxane A2 amplify and sustain the initial platelet response, and recruit 
circulating platelets to form a growing hemostatic plug [104]. Transmembrane signalling by 
ligated receptors activates the platelets and induces α-granule release with the secretion of 
various procoagulant molecules such as factor V, vWF and fibrinogen. Activated platelets 
undergo a flip-flop reaction exposing phosphatidylserine to the outer membrane leaflet. The 
phospholipids provide a surface for the assembly of coagulant enzyme complexes which 
generate thrombin and enable fibrin deposition, stabilizing the clot. 
It is well recognized that platelets play an important role in the pathophysiological 
development of atherothrombosis [104]. Recent evidence also suggest that platelets contribute 
to the progress of atherosclerotic lesions by numerous inflammatory properties [104]. In acute 
atherothrombosis, platelets rapidly adhere to the site of plaque disruption and initiate the 
coagulation process, resulting in thrombus formation [74]. The sequence of events leading to 
venous thrombi is less clear. Venous and arterial thrombi differ in composition, as arterial 
thrombi predominantly consist of platelets and a small amount of fibrin and red cells, while 
venous thrombi predominantly consist of red cells and fibrin. Based on the histopathologic 
structure of venous thrombi, platelet aggregation has traditionally not been considered an 
important pathophysiological mechanism of thrombus formation within the venous system. 
However, experimentally induced venous thrombus in the presence of radiolabeled platelets 
shows early accumulation of platelets at the head of the thrombus [105]. Moreover, 
antiplatelet agents have been shown to be effective for prevention of venous thromboembolic 
disorders, although to a smaller extent than anticoagulants [106,107]. 
The impact of platelet function and platelet count on the risk of VTE has not been 
extensively examined in prospective studies. Only a few studies have investigated the 
relationship between platelet count and VTE. In the LITE-study [11], a prospective study of 
19 293 men and women followed for a mean of 7.8 years, elevated platelet count was not 
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associated with increased risk of VTE. Likewise, a prospective follow-up study of 5 766 
elderly showed no association between platelet count and VTE [108]. Furthermore, limited 
data exists on the relationship between platelet function and VTE. Recently, increased levels 
of P-selectin, a marker of platelet activation, have been shown in VTE patients [109], and 
higher circulating P-selectin was associated with increased risk of recurrent VTE in patients 
with first unprovoked VTE [110].  
Platelet size, measured as mean platelet volume (MPV), is a marker of platelet 
function. Increased platelet volume is correlated with increased platelet reactivity [111], 
shortened bleeding time [111] and increased platelet aggregation ex vivo [112]. Large 
platelets have a higher thrombotic potential than small platelets [113], and express higher 
levels of platelet activation markers, such as P-selectin [114]. Studies have shown increased 
levels of MPV in patients with CAD [115,116], and MPV has been identified as an 
independent risk factor for MI and stroke [117-119]. To date, no study has investigated a 




2. AIMS OF THE STUDY 
 
The aims of the study were: 
 
• To investigate the impact of traditional cardiovascular risk factors on the risk of 
venous thromboembolism in a prospective, population-based cohort-study. 
 
• To examine the association between the metabolic syndrome and its individual 
components on the future risk of venous thromboembolism. 
 
• To investigate the impact of HDL-cholesterol on the incidence of venous 
thromboembolism. 
 





3. STUDY POPULATION AND METHODS 
 
3.1 The Tromsø Study  
 The Tromsø Study is a single centre longitudinal population study with repeated health 
surveys of inhabitants in the municipality of Tromsø, Norway. The study is conducted by the 
Institute of Community Medicine at the University of Tromsø, and the main focus is on 
cardiovascular disease. The first survey was carried out in 1974, followed by surveys in 1986-
87, 1994-95, 2000-01, and 2007-08. 
The fourth survey of the Tromsø Study (Tromsø IV) was conducted in 1994-95 and 
comprised two screening visits with an interval of 4-12 weeks. All inhabitants aged > 24 years 
were invited to the first screening visit, and a total of 27 158 subjects participated (77 % of the 
eligible population). All participants aged 55 to 74 years and 5-10% samples in the other 5-
year birth cohorts (25-54 years and ≥ 75 years) were invited to a more extensive second visit, 
and a total of 6 889 subjects participated (78 % of the eligible population).  
The four papers included in this thesis are all based on a prospective follow-up study 
on subjects who participated in Tromsø IV. Participants were followed from the date of 
enrolment in 1994-95 through September 1, 2007, and all first lifetime events of VTE during 
this 14-year study-period were recorded.  
 
 
3.2 Baseline measurements - cardiovascular risk factors (Tromsø IV) 
Baseline information on cardiovascular risk factors was collected by physical 
examinations, blood samples and self-administered questionnaires. Blood pressure was 
recorded with an automatic device (Dinamap Vital Signs Monitor), by specially trained 
personnel. Participants rested for 2 minutes in a sitting position, and then three readings were 
taken on the upper right arm, separated by 2-minute intervals. The average of the two last 
readings was used in the analysis. Height and weight were measured with subjects wearing 
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light clothing and no shoes. BMI was calculated as weight in kilograms, divided by the square 
of height in meters (kg/m2). Waist circumference was measured at the umbilical line. Non-
fasting blood samples were collected from an antecubital vein, serum prepared by 
centrifugation after one hour respite at room temperature, and further analyzed at the 
Department of Clinical Chemistry, University Hospital of North Norway. Serum total 
cholesterol and triglycerides were analyzed by enzymatic, colorimetric methods and 
commercially available kits (CHOD-PAP for cholesterol, and GPO-PAP for triglycerides: 
Boeringer Mannheim). Serum HDL-cholesterol was measured after precipitation of lower-
density lipoproteins with heparin and manganese chloride. Determination of glycosylated 
haemoglobin (HbA1c) in EDTA whole blood was based on an immunoturbidometric assay 
(UNIMATES, F. Hoffmann-La Roche AG: Basel, Switzerland). The HbA1c percent value 
was calculated from the HbA1c/haemoglobin ratio. For measurements of MPV and platelet 
count, 5 ml blood were drawn into vacutainer tubes, containing EDTA as an anticoagulant (K3 
– EDTA 40 µl, 0.37 mol/L per tube), and analysed within 12 hours in an automated blood cell 
counter (Coulter Counter®, Coulter Electronics, Luton, UK). Information on self-reported 
diabetes, current smoking and family history of MI was collected from a self-administered 
questionnaire. The questionnaire is presented in the appendix.  
 
 
3.3 Outcome measurements - venous thromboembolism  
All first lifetime events of VTE during follow-up were identified by searching the 
computerized index of medical diagnoses, the autopsy registry and the radiology procedure 
registry at the University Hospital of North Norway. The University Hospital of North 
Norway is the only hospital in the Tromsø region, and all hospital care and relevant diagnostic 
radiology in the Tromsø community is provided exclusively by this hospital. The relevant 
discharge codes were ICD-9 codes 325, 415.1, 451, 452, 453, 671.3, 671.4, 671.9, for the 
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period 1994-1998, and ICD-10 codes I26, I80, I81, I82, I67.6, O22.3, O22.5, O87.1, O87.3 
for the period 1999-2007. The index of medical diagnoses included diagnoses from outpatient 
clinic visits and hospitalizations. An additional search through the computerized index of 
autopsy diagnoses was conducted, and cases diagnosed with VTE, either as a cause of death 
(part one of the death certificate), or as a significant condition (part two of the death 
certificate), were identified. We also searched the radiology procedure registry to identify 
potential cases of objectively confirmed VTE that may have been missed because of coding 
errors in the index of medical diagnoses. All relevant diagnostic procedures performed at the 
Department of Radiology, to diagnose VTE during the 14-year period, were systematically 
reviewed by trained personnel, and cases with objectively confirmed VTE were identified.  
The medical records for each potential VTE-case, derived from the medical diagnostic 
index, the autopsy registry, or the radiology procedure registry, were reviewed by trained 
personnel. The personnel were blinded to the baseline variables, including family history of 
MI. For subjects derived from the medical diagnostic index and the radiology procedure 
registry, an episode of VTE was verified and recorded as a validated outcome when all four of 
the following criteria were fulfilled; (i) objectively confirmed by diagnostic procedures 
(compression ultrasonography, venography, spiral computed tomography, perfusion-
ventilation scan, pulmonary angiography or autopsy), (ii) the medical record indicated that a 
physician had made a diagnosis of DVT or PE, (iii) signs and symptoms consistent with DVT 
or PE were present and (iv) the patient underwent therapy with anticoagulants (heparin, 
warfarin, or a similar agent), thrombolytics or vascular surgery. For subjects derived from the 
autopsy registry, a VTE-event was recorded as an outcome when the autopsy record indicated 





4. MAIN RESULTS  
 
4.1 Paper I:  
FAMILY HISTORY OF MYOCARDIAL INFARCTION IS AN INDEPENDENT RISK 
FACTOR FOR VENOUS THROMBOEMBOLISM – THE TROMSØ STUDY. 
 
Familial aggregation of coronary heart disease is a strong and independent risk factor for 
arterial cardiovascular events. This prospective, population-based study was conducted to 
determine the impact of cardiovascular risk factors, including family history of MI, on the 
incidence of VTE. Traditional cardiovascular risk factors and family history of MI were 
registered in 21 330 subjects, aged 25-96 years, enrolled in the Tromsø Study in 1994-95. 
First-lifetime VTE-events during follow-up were registered up to September 1st 2007. There 
were 327 VTE-events of which 138 (42%) occurred unprovoked during a mean of 10.9 years 
of follow-up. In age- and gender-adjusted analysis, age (HR per decade: 1.97, 95 % CI: 1.82-
2.12), gender (men vs. women HR: 1.25, 95 % CI 1.01-1.55), BMI (HR per 3 kg/m2: 1.21, 95 
% CI: 1.13-1.31), and family history of MI (HR: 1.31, 95 % CI: 1.04-1.65) were significantly 
associated with VTE. Family history of MI remained a significant risk factor for both total 
and unprovoked VTE in multivariable analysis. Blood pressure, total cholesterol, HDL-
cholesterol, triglycerides and smoking were not independently associated with total VTE. 
HDL-cholesterol was significantly associated with increased risk of unprovoked VTE in 
multivariable analysis. To the best of our knowledge, this was the first study identifying an 
association between family history of MI and VTE. In conclusion, family history of MI as an 
independent risk factor for VTE provides further evidence to the concept of a link between 
arterial and venous thrombosis. Traditional cardiovascular risk factors did not seem to be 
underlying determinants for this association, suggesting that family members share yet 
unknown genetic or environmental risk factors.  
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4.2 Paper II:  
ABDOMINAL OBESITY IS ESSENTIAL FOR THE RISK OF VENOUS 
THROMBOEMBOLISM IN THE METABOLIC SYNDROME - THE TROMSØ 
STUDY. 
 
This study was undertaken to investigate whether the metabolic syndrome, and its individual 
components, was associated with increased risk of venous thromboembolism (VTE). 
Individual components of the metabolic syndrome were registered in 6170 subjects aged 25 to 
84 years who attended the second screening visit of the Tromsø Study in 1994-95, and first 
lifetime events of VTE were registered until September 1st 2007. The metabolic syndrome 
was present in 21.9 % (1350 subjects) of the population. There were 194 validated first VTE 
events (2.92 per 1000 person-years) during a mean of 10.8 years of follow up.  Subjects with 
the metabolic syndrome had increased risk of VTE (HR: 1.65, 95 % CI: 1.22-2.23) in age- 
and gender-adjusted analysis. Furthermore, the risk of VTE increased with the number of 
components in the metabolic syndrome (p<0.001). Among the individual components of the 
syndrome, abdominal obesity was the only component significantly associated with VTE in 
multivariable analysis including age, gender and the other individual components of the 
syndrome (HR: 2.03, 95% CI: 1.49-2.75). When abdominal obesity was omitted as a 
diagnostic criterion in a modified definition of the syndrome, none of the other components, 
alone or in cluster, was associated with increased risk of VTE. In fact, the risk associated with 
abdominal obesity alone was higher than the risk associated with the metabolic syndrome. In 
conclusion, this study provided evidence for the metabolic syndrome as a risk factor for VTE. 
Moreover, abdominal obesity appeared to be the crucial risk factor among the individual 
components of the syndrome.  
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4.3 Paper III:  
HDL-CHOLESTEROL AND FUTURE RISK OF VENOUS THROMBOEMBOLISM – 
THE TROMSØ STUDY. 
 
The purpose of this study was to determine the impact of HDL-cholesterol on VTE risk in a 
large prospective, population-based study. Risk factors, including HDL-cholesterol, were 
registered in 26 676 subjects, aged 25-96 years, enrolled in the Tromsø Study in 1994-95, and 
incident VTE events were registered during follow-up until 1 September 2007. There were 
458 VTE events of which 191 (41.7 %) occurred unprovoked. HDL-cholesterol was not 
associated with risk of total VTE. The multivariable-adjusted HR per 0.5 mmol/L HDL-
cholesterol was 1.08 (95 % CI: 0.93-1.26) in women and 1.10 (95 % CI: 0.91-1.32) in men. 
When analysing unprovoked VTE separately, multivariable-adjusted HR per 0.5 mmol/L 
HDL-cholesterol was 1.39 (95 % CI: 1.10-1.75) in women and 1.15 (95 % CI: 0.87-1.53) in 
men. HRs by quartiles of HDL-cholesterol revealed that women in the upper quartile had 
significantly 1.87-fold (95 % CI: 1.01-3.47) increased risk of unprovoked VTE compared to 
subjects in the lowest quartile (p for trend across quartiles=0.03). There was no significant 
trend (p=0.2) across HDL-cholesterol quartiles in men. In conclusion, our findings challenge 
the concept that high HDL-cholesterol protects against venous thrombosis.  Further studies 
are needed to determine whether the apparent increased risk of unprovoked VTE by HDL-




4.4 Paper IV:  
MEAN PLATELET VOLUME IS AN INDEPENDENT RISK FACTOR FOR VENOUS 
THROMBOEMBOLISM – THE TROMSØ STUDY 
 
The purpose of the study was to determine the impact of platelet count and platelet size, 
measured as MPV, on the incidence of VTE in a prospective, population-based study. Platelet 
count, MPV and baseline characteristics were registered in 25 923 subjects aged 25 to 96 
years, who participated in the fourth survey of the Tromsø Study in 1994-95. Incident VTE-
events were registered through end of follow-up (September 1, 2007). During the study period 
there were 445 validated incident VTE events (1.6 per 1000 person-years), of which 186 
(42%) were unprovoked. Mean follow-up time was 10.8 years. Increasing levels of MPV was 
associated with increased risk of total VTE (p for trend=0.09), and unprovoked VTE (p for 
trend=0.03) in analysis adjusted for age and sex. Subjects with MPV ≥9.5 fL had a 1.3-fold 
(95% CI: 1.0-1.7) higher risk of total VTE, and a 1.5-fold (95% CI: 1.1-2.3) higher risk of 
unprovoked VTE compared to subjects with MPV<8.5 fL in analysis adjusted for age, sex, 
smoking, BMI and platelet count. There was no significant association between increasing 
platelet count and risk of VTE. In conclusion, increasing levels of MPV was identified as a 
predictor for VTE, in particular VTE of unprovoked origin. The present findings support the 
concept that platelet reactivity is important in the pathogenesis of venous thromboembolism. 
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5. GENERAL DISCUSSION 
5.1 Methodological considerations 
Study design 
The four papers presented in this thesis are all based on a large prospective cohort study. 
Cohort studies have several advantages. First, there is the clear temporal sequence of exposure 
and outcome, which is essential to establish some indication of causality. Second, the cohort 
study is more likely to obtain valid and unbiased information on the subject’s exposure 
compared to a retrospective study. Another advantage of cohort studies is the large number of 
study subjects, which enhances the generalizability and external validity. Cohort studies are 
usually ethically safe due to their non-experimental nature. A problem with the cohort method 
occurs when the incidence of disease is low, and large numbers of people must be followed up 
for long periods before sufficient cases accrue to give statistically meaningful results.  
Cohort studies have major advantages compared to case-control studies in measuring 
possible associations between exposure and disease. The retrospective nature of case-control 
studies results in an indecisive sequence of exposure and outcome, and it cannot be definitely 
established whether the associated variable is a response to rather than a cause of the disease. 
Validation of information on exposure may be difficult, and there is a risk of recall bias 
particularly related to self-reported exposure. A case-control study can generate a hypothesis 
of causality, but can not be used to establish a cause-and-effect relationship. 
Cohort studies are similar to randomised controlled trials (RCT) in that they compare 
outcomes in subjects who have or have not been exposed to a variable of interest. The main 
difference is that in cohort studies, allocation of individuals is not by chance. Thus, one 
cannot definitely establish whether the observed difference in outcomes between the two 
comparison groups is attributed to the exposure rather than other factors (confounders). 
According to the Bradford-Hill criteria of causality [120], a cause-and-effect relationship 
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depends on a temporal relationship, the strength of the association, and that there is a dose-
response relationship between exposure and risk. All these factors can be assessed by a cohort 
study. However, the Bradford-Hill criteria also require experimental evidence for assessment 
of causality, i.e. that the outcome can be altered by an appropriate experimental regimen 
altering exposure. The cohort is insufficient in this matter. Thus, the cohort study can be used 
to measure associations, but not establish causality.  
The RCT is the gold standard for establishing cause-and-effect relationships. RCTs are 
experimental comparison studies in which participants are allocated to intervention or control 
groups using a random mechanism. In our cohort study, we found a strong and independent 
association between obesity and VTE. Thus, an appropriate way to further examine a cause-
and-effect relationship between obesity and VTE would be to conduct a RCT investigating the 
impact of weight reduction on risk of VTE. The drawbacks of RCTs are that they are 
expensive and time consuming, and can sometimes be ethically problematic. The 
generalizability of a RCT can also be limited due to very strict inclusion and exclusion 
criteria. For some conditions, RCTs are not suitable, and cohort studies remain the best 
alternative for investigating possible exposure-outcome relations.  
 
Generalizability 
The findings of a study are generalizable if the results are applicable to other 
populations. The Tromsø study is based on a general adult population. All inhabitants in the 
municipality of Tromsø aged 25 or older were invited to our study, and the attendance rate 
was high; 77 % of the eligible population participated. The age and sex distribution of the 
Tromsø population is not substantially different from Western populations regarding the 
incidence and prevalence of cardiovascular diseases, educational levels, and social and 
lifestyle factors. The incidence of VTE found in our study is comparable to other Western 
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populations [44,121]. Even though our study population was recruited from a general 
population with high attendance rate, selection bias due to lower attendance rate in severely ill 
and disabled individuals is likely to have occurred. Furthermore, the age-specific attendance 
rates where somewhat lower in the younger (<40 years) and older (≥80 years) age groups, and 
this may influence the representativeness of the results for these age groups. 
 
   
Confounding 
In cohort studies, confounding is a potential problem for assessment of causality [122]. 
Ideally, the comparison groups in a cohort study should be identical apart from the exposure 
variable of interest. However, in reality this situation does not exist due to the non-
randomized nature of cohorts [123]. A confounding factor is a factor that is related to both the 
exposure and outcome; or more exactly, a factor that differs between the comparison groups 
and predicts the outcome variable [122,124]. Confounding can cause bias in either directions; 
both over- and underestimate the actual effect. Bias introduced by confounding can also 
occasionally be strong enough to reverse the apparent direction of an effect [125].   
Stratification and multivariable analysis are strategies to control or minimize 
confounding [126]. Stratification describes a process where the sample is divided into 
subgroups on the basis of characteristics thought to confound the analysis. This method was 
used in paper III. Subjects were stratified by gender as levels of HDL-cholesterol are known 
to differ in men and women. Multivariable analysis is a statistical tool for determining the 
independent contribution of each risk factor to a single outcome [124]. In paper I, risk 
estimates for VTE were presented in age- and gender-adjusted analysis, as well as in a 
multivariable model including all the potential cardiovascular risk factors examined in the 
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study. Likewise, in paper IV risk estimates were adjusted for age and gender and in a 
multivariable model including other potential confounders.  
Even if a confounder is known, there may be insufficient data to evaluate it. In our 
study we did not have baseline information on inherited thrombophilic disorders, which are, 
of course, potential confounders. However, information on thrombophilic factors measured in 
the VTE-patients at the time of the event, revealed that one or more thrombophilic factor 
(APC-resistance, protein C-, protein S- or antithrombin-deficiency or lupus anticoagulant) 
was present in only 16 % of those with an unprovoked event, suggesting that most of the 
unprovoked events apparently was caused by other risk factors. We are not aware of any 
publications that have established an interrelation between inherited thrombophilic disorders 
and the risk factors investigated in papers I-IV. Thus, we do not believe that inherited 
thrombophilic disorders represent unrecognized confounders in our study.  
 
Misclassification and information bias 
Although cohort studies allow complete and validated baseline data, sometimes 
exposure information can be sparse because the large number of subjects does not permit long 
interviews, and questionnaires can be difficult to complete properly. Erroneous information 
from study subjects can produce systematic error in studies. Misclassification of subjects for 
either exposure or disease can be differential (related to the occurrence of disease) or 
nondifferential (not related to occurrence of disease). In a prospective cohort study, exposure 
is measured before the development of disease, and hence exposure-misclassification is 
generally nondifferential.  
Self-reported data is a possible source to misclassification. In our study, self-reported 
dichotomous data collected from the questionnaire included diabetes, smoking and family 
history of disease. Both underreporting and overreporting of these variables are possible. 
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Current guidelines provide established cut-off values for diabetes mellitus based on fasting 
blood glucose levels [127]. The prevalence of diabetes type 2 is reported to be approximately 
10 %, and is increasing in western countries [128]. Screening for type 2 diabetes is not carried 
out on a regular basis, and it is likely that a number of subjects are undiagnosed according to 
the established criteria [129]. The prevalence of self-reported diabetes in our study was lower 
than 2 %, which is substantially lower than expected. Thus, it is likely that self-reported 
diabetes in our study provides an underestimate of the true prevalence for diabetes. When 
completing questionnaires, study subjects may wish to report behaviours consistent with a 
healthy lifestyle. Self-report of smoking has been shown to underestimate the true prevalence 
in some studies [130,131], whereas others have found self-reported smoking status to be 
reasonably valid [132]. In a validation study on the reliability of reported family history of 
MI, Kee at al. demonstrated a high specificity (97 %) and a somewhat lower sensitivity (68 
%) of reporting a positive family history of MI [133]. Thus, underestimation of the risk 
associated with family history of MI is more likely.  
In our study, blood samples for measurement of serum lipid levels were drawn in a 
non-fasting state between 08.00 hours and 20.00 hours. The use of non-fasting blood samples 
may represent another possible source of misclassification, as current guidelines recommend 
measurement of a fasting lipid profile for assessment of cardiovascular risk [59]. However, 
total cholesterol and HDL-cholesterol does not exhibit any substantial diurnal variation [134] 
or postprandial changes [135-137], and thus we believe that the use on non-fasting samples 
had negligible impact on our results regarding cholesterol. In contrast, triglyceride levels vary 
substantially during the day [134] and increases significantly following a high-fat meal [137], 
suggesting that fasting levels are recommended. On the other hand, the fasted state is a 
relatively artificial metabolic condition as our body spends most of the day in a postprandial 
environment. Thus, one might argue that non-fasting lipid levels possibly represent a more 
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accurate assessment of lipid status. Recently, a study by Mora et al. [138] reported that 
associations with CVD was similar for fasting and non-fasting total cholesterol and HDL-
cholesterol, and stronger for non-fasting triglycerides compared to fasting values, suggesting 
that non-fasting lipid samples are preferable for assessment of CVD-risk.  
 
Modifiable risk factors 
The optimal follow-up time for detection of outcome after exposure may vary due to 
the causal mechanism and biology of the disease. Modifiable risk factors are a potential 
limitation of cohort-studies, especially when the time between exposure and disease 
manifestation is very long. In our study, subjects were followed for a mean of 10.8 years 
(median 12.5), and the individual risk profile may have changed during this period in some 
subjects, as most of the cardiovascular risk factors are modifiable. This kind of 
misclassification generally leads to underestimation of the associated risk, due to regression 
dilution bias [139]. 
 
Missing values 
Missing observations are quite common in large cohorts. Missing may be due to 
various reasons, e.g. subjects do not respond adequately to questionnaires, subjects are lost to 
follow-up, occasional missing values because some equipment failed during measurements, or 
laboratory samples are lost in transition or technically unsatisfactory [140]. The question of 
how to handle missing data is controversial, and there are various approaches on how to 
handle missing data in analysis. One alternative is to omit variables with many missing data. 
Another approach is to omit individuals who do not have complete data, which is probably the 
most common method [140]. The third alternative is to use imputation techniques to replace 
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missing values. In general, imputation techniques are based on replacement of missing values 
by a plausible value predicted from an individual’s available dataset. 
The main concern is whether the presence of missing has introduced bias. In paper I 
presented in this thesis, about 20 % of the participants did not complete the questions on 
family history of MI. We chose to do available-case analysis, and subjects with missing 
values were excluded from the study population. An important question to investigate was 
whether the study population (available-case population) differed from the source population. 
In order to assess the representativeness of the study population, we compared the risk 
estimates (HRs) for all traditional cardiovascular risk factors other than family history of MI 
in the study population and the source population. The HRs for each of the other traditional 
cardiovascular risk factors were essentially identical in the two populations, implying that the 
study population presumably was representative for the source population. We also explored 
the extremes of our missing data on family history of MI, by performing analysis where we 
assumed that the answer of all non-responders was negative. In these analyses the risk 
estimate for family history of MI was slightly attenuated, as expected, but it was still 
increased, and considered strong enough to support our assumptions of a robust association. 
 
Detection and validation of outcome 
In our study, VTE-events among the study participants during follow-up were registered 
retrospectively by using the medical diagnostic index, the radiology procedure register, and 
the autopsy register at the University Hospital of North-Norway. This hospital exclusively 
provides health care services to the inhabitants in the Tromsø municipality, which enhances 
the probability of a complete VTE-register. However, some cases of VTE can possibly have 
been missed if they were diagnosed and treated elsewhere. In order to make the manifestation 
of disease as certain as possible, our validation of outcome was dependent on four solid 
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criteria. The VTE-event should be (i) objectively confirmed by diagnostic procedures 
(compression ultrasonography, venography, spiral-CT, perfusion-ventilation scan, pulmonary 
angiography or autopsy) and (ii) the medical record should indicate that a physician had made 
a diagnosis of DVT or PE. Furthermore, (iii) signs and symptoms consistent with DVT or PE 
should be present, and (iv) the patient should receive therapy with anticoagulants (heparin, 
warfarin, or a similar agent) thrombolytics or vascular surgery, unless a specific reason for not 
providing treatment were specified in the medical record. We wanted to ensure that all cases 
were significant and incident clinical events and the four criteria were combined in order to 
avoid false positive VTE-cases. For instance, by using these criteria, an asymptomatic venous 
thrombi of undefined age accidentally discovered by computed tomography and not treated 
with anticoagulants (or similar agent) would not be considered a clinical event. 
Despite the use of firm criteria for outcome validation, misclassification of VTE-cases 
cannot be completely ruled out. Retrospective registration is dependent on valid and complete 
information, and thus insufficient information from patient records could lead to inaccuracy. 
Furthermore, there were no standard instructions for reporting presence of clinical risk factors 
and provoking factors for VTE in the medical record, and classification of events as 
unprovoked or provoked relied on information provided by the individual physician who 
examined the VTE-patient. Since the personnel who registered the VTE-events were blinded 
to the baseline information, any misclassification of VTE was most likely nondifferential. 
Nondifferential outcome misclassification generally leads to underestimation of the true 
outcome-exposure association [125]. This is in contrast to differential outcome 
misclassification which could introduce a false positive/negative outcome-exposure 
association.  
Unfortunately, we did not have verified baseline information on previous history of 
VTE among the study-subjects. Hence, some of the subjects who were treated as healthy 
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participants during follow-up could be prevalent VTE-cases who should have been excluded 
from the study population. However, this would lead to only a small change in the overall 
number of person-years at risk, and thus would presumably have a negligible influence on the 
risk estimates.  
 
5.2 Discussion of main results 
Serum lipid levels and VTE 
Dyslipidemia is associated with hypercoagulability, endothelial dysfunction and 
increased platelet aggregation [57,141,142]. An unfavourable lipid profile, including high 
levels of triglycerides, high LDL-cholesterol and low HDL-cholesterol, is a well established 
risk factor for development of atherosclerosis and arterial cardiovascular disease.  
In the recent years, there has been increasing interest in investigating the possible 
relationship between serum lipid levels and risk of venous thrombosis. High levels of 
triglycerides [57,98,143] and lipoprotein A [144,145] have been associated with increased 
risk of VTE in case-control studies. A retrospective cohort study of 125 862 men and women 
aged ≥ 65 years reported a 22% relative risk reduction in the risk of DVT among statin users 
[146]. Recently, a RCT showed that 20 mg rosuvastatin daily significantly reduced the 
occurrence of symptomatic VTE [147]. However, the risk-reduction appeared to be 
independent of lipid status [147], suggesting that the effect was caused by other 
antithrombotic properties of statins [148]. In our study, elevated triglyceride levels (paper I 
and II) and total cholesterol (paper I) showed no association with VTE. These findings are in 
agreement with both the LITE-cohort [11] and the cohort of Swedish men [15].  
Whether isolated hypertriglyceridemia is atherogenic in the absence of either increased 
LDL-cholesterol or decreased HDL-cholesterol has been a matter of dispute [149]. There is 
evidence for triglycerides as an independent risk factor for CAD in certain subgroups, but the 
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evidence for triglycerides as a synergistic CAD risk factor is stronger [149]. In our study, we 
investigated whether triglycerides were independently associated with VTE. For further 
research, a comparison study on risk factors for VTE and CAD within the same population is 
probably useful to determine and compare the impact of triglycerides and cholesterol on the 
individual prediction of these conditions. Another interesting approach is to investigate the 
relationship between postprandial hyperlipidemia and VTE, as postprandial hyperlipidemia 
may prove a better indicator of atherogenicity [150].  
Low HDL-cholesterol is an established risk factor for CAD [76], a concept supported 
by the antiatherogenic and antithrombotic properties of HDL [78,88]. Several case-control 
studies [56,57,97] and a prospective cohort study [55] have suggested that high levels of 
HDL-cholesterol are protective against VTE. However, other prospective studies have failed 
to show this relationship [11]. Low HDL-cholesterol was not associated with risk of VTE in 
our population (paper II and III). In fact, high levels of HDL-cholesterol were apparently 
associated with increased risk of unprovoked VTE in women, a finding supported by data 
from the LITE cohort study [101] and the Women’s Health Study [151]. The apparent 
inconsistency between the abovementioned studies may rely on several methodological 
factors. The nature of case-control studies does not allow determining whether the observed 
HDL-cholesterol level is a response to rather than a cause of VTE. Inflammatory markers, 
such as fibrinogen, C-reactive protein (CRP) and white blood cell count, has not been 
associated with future risk of VTE [152], but VTE is associated with elevated serum levels of 
high sensitivity-CRP (hs-CRP) after the acute event [153], and hs-CRP is known to be an 
inverse predictor of HDL-cholesterol [154]. Similarly to acute CAD [155,156], it is likely to 
assume that HDL-cholesterol would decline following an acute VTE-event. In the largest 
case-control study among postmenopausal women, HDL-cholesterol was measured prior to 
the VTE event and showed no significant association between HDL-cholesterol and risk of 
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VTE in quartile-based analysis and adjusted odds ratios [57]. Similarly, low HDL-cholesterol 
was not associated with increased risk of VTE in young women after adjustment for BMI 
[99]. A third case-control study reported only an inverse association between HDL-
cholesterol and VTE risk in the lowest tentile of HDL-cholesterol in men, but not in women 
[98]. The strongest association between HDL-cholesterol and risk of VTE appeared in a 1:1 
matched case-control study among 49 male VTE patients less than 55 years of age in which 
controls were recruited among healthy blood donators and not from the general population 
[56]. The prospective cohort study [55] reported significantly lower crude HDL-cholesterol at 
baseline among subjects who developed VTE during 23 years of follow-up. However, no risk 
estimates for VTE was presented, neither in crude nor adjusted analysis, and thus potential 
confounders for this observed relationship could not be assessed [55]. In summary, the 
methodological considerations of the studies reporting an inverse relation between HDL-
cholesterol and risk of VTE weaken the evidence in favour of HDL-cholesterol as a protective 
factor for venous thrombosis. 
In our study, HDL-cholesterol was apparently positively associated with increased risk 
of unprovoked VTE in women, and a similar tendency was found in the LITE-study [101]. 
Estrogen supplementation is known to increase HDL-cholesterol [157] and the risk of VTE 
[158,159]. However, the increased risk of VTE by HDL-cholesterol in women was probably 
not explained by estrogen supplementation or menopausal status as adjustment for these 
variables did not attenuate the HR. The antithrombotic properties of HDL particles may imply 
that HDL-cholesterol is a marker rather than a mediator of increased risk of unprovoked VTE, 
particularly among women. Further studies are warranted to determine whether the apparent 
increased risk of unprovoked VTE by HDL-cholesterol in women is a direct effect of HDL or 
due to unrecognized confounders.  
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Serum lipid levels including total cholesterol, triglycerides and HDL-cholesterol 
(inverse) are related to risk of atherosclerosis and development of arterial cardiovascular 
disease. In the recent years, increasing evidence suggest a link between arterial and venous 
thrombosis, possibly through the pathophysiological process of atherosclerosis, or the sharing 
of common risk factors [45,52,54]. Based on the existing literature and the present findings of 
our study, we conclude that serum lipid levels, including total cholesterol, HDL-cholesterol 
and triglycerides, are not independently associated with risk of VTE, and that the apparent 
relationship between arterial and venous thrombosis probably is due to other risk factors or 
mechanisms. On the other hand, postprandial lipemia as a risk factor for VTE cannot be ruled 
out. Experimental studies have shown that very low density lipoprotein (VLDL) enhances 
prothrombin activation by factor Xa in the presence of factor Va [160,161]. Studies in healthy 
individuals and patients with combined hyperlipidemia have reported increased coagulation 
activation, assessed by plasma levels of activated factor VII [162-165] and endogenous 
thrombin generation [164], during the postprandial state. Moreover, dietary low fat intake 
[166], intervention with polyunsaturated n-3 fatty acids supplementation [163,164] and 
cholesterol-lowering treatment [163,164] is reported to decrease coagulation activation during 
the postprandial phase. So far, no study has investigated the impact of postprandial 




Other cardiovascular risk factors and VTE 
 Age, BMI, family history of MI and MPV were recognized as risk factors for VTE in 
the papers (I-IV) presented in this thesis, whereas serum lipid levels, smoking, hypertension 
and diabetes showed no association with VTE. The metabolic syndrome was significantly 
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associated with VTE, but this association was fundamentally dependent on the presence of 
obesity.   
 Smoking is a well known risk factor for MI and stroke [167]. In agreement with other 
prospective studies [5,11], there were no association between smoking, expressed as a 
dichotomous variable (current smoking yes/no), and VTE in our study (paper I). Heavy 
smoking has been associated with increased risk of PE in women [14] and VTE in men [15]. 
Investigating various degrees of smoking may be a better approach to assess the possible 
relationship between smoking and risk of VTE in the future.  
 Hypertension defined by the NCEP-ATPIII criteria was not associated with VTE in 
our study (paper II). Likewise, neither systolic nor diastolic blood pressure showed any 
relation with increased risk of VTE (paper I). The Nurses’ Health Study found that self-
reported hypertension was related to increased risk of PE [14], and the Copenhagen City 
Heart Study reported a higher crude proportion of baseline hypertension in subjects with VTE 
[55]. However, in agreement with our results, most prospective studies including the LITE-
study [11], the Physicians’ Health Study [5] and the cohort of Swedish men [15] found no 
relationship between blood pressure and VTE, suggesting that hypertension is not an 
independent risk factor for venous thrombosis.  
Previous reports from prospective studies are conflicting with regard to the impact of 
diabetes on risk of VTE. The LITE-study [11] reported that diabetes was associated with 
increased risk of VTE, whereas the Physicians’ Health Study [5] and the Nurses Health Study 
[14] found no association. In our study (paper I), subjects with self-reported diabetes had a 
2.5-fold higher incidence rate of VTE, and a non-significantly 1.4-fold increased risk of VTE. 
In multivariable analysis including BMI, the association disappeared. Furthermore, impaired 
glucose tolerance defined as HbA1c ≥ 5.6 mmol/L showed no independent association with 
VTE (paper II). As previously described in this thesis, self-reporting of data enhances the risk 
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of misclassification, and thus may conceal the magnitude of the true association. Blood 
glucose levels were not measured in the entire cohort and self-reported diabetes was the only 
available variable for this condition. In the LITE-cohort, diabetes was defined as fasting 
glucose levels of ≥7mmol/L, non-fasting glucose levels of ≥11.1 or a history of treatment for 
diabetes, and the prevalence of diabetes was substantially higher than in our study (11.8 % vs 
1.4 %). Regarding diabetes and risk of VTE, the apparent inconsistency between studies may 
to some extent rely on different diagnostic criteria for diabetes.  
Obesity could be a key factor in the observed association between arterial and venous 
thrombosis. Obesity is clearly related to increased risk of both conditions, however, it is 
apparently a more important risk factor for VTE compared to arterial events like MI and stroke 
[5]. In paper II, we demonstrated that obesity was clearly essential for the observed increased 
risk of VTE associated with the metabolic syndrome. Obesity is associated with raised intra-
abdominal pressure and reduced venous blood flow velocity which may render blood more 
susceptible to thrombosis in the deep veins [168,169]. Furthermore, visceral adipose tissue is 
highly metabolic active, releasing increased amounts of proinflammatory-, proatherogenic- and 
prothrombotic substances [170], which may be a common pathophysiological explanation for 
the observed risk of thrombosis in both the arterial and venous systems.  
 Familial aggregation of coronary heart disease is a strong and independent risk 
factor for arterial cardiovascular events [171,172]. We have for the first time identified an 
association between family history of MI and VTE (paper I). Traditional cardiovascular risk 
factors, including age, hypertension, serum lipid levels, obesity, smoking and diabetes did not 
seem to be underlying confounders for this association (paper I).  
Atherosclerosis is associated with endothelial dysfunction, coagulation activation and 
platelet activation [173], with a subsequent increase in risk of arterial thrombosis [174,175]. 
Family history of cardiovascular disease has previously been identified as a predictor for 
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subclinical carotid atherosclerosis [176], and to be an independent predictor for coronary 
calcification in young subjects [177]. Moreover, a higher frequency of carotid plaques [45] 
and coronary calcification [178,179] has been reported in patients with VTE, and it has also 
been shown that a first arterial cardiovascular event is associated with subsequent 
development of VTE [46]. Thus, it is not unreasonable to suggest that a plausible 
pathophysiological link exist between atherosclerosis and VTE. However, as described in the 
introduction of this thesis, the impact of subclinical atherosclerosis as a risk factor for VTE is 
controversial [45-47]. In summary, subclinical atherosclerosis cannot be ruled out as a 
plausible link between arterial and venous thrombosis, but further research, preferably 
prospective cohorts of general populations with a wide age range, is essential to establish the 
true nature of this relationship.  
Although atherosclerosis may represent a possible link, the apparent lack of 
association with traditional cardiovascular risk factors, presented in our work, indicate that 
also other factors than the atherosclerotic process itself may contribute to the link between 
arterial and venous thrombosis. Moreover, the sequence of thrombotic events is not 
predetermined, as patients who have suffered a VTE event, also are reported to have increased 
risk of an arterial thromboembolic event during long-term follow up [52]. Altogether, these 
findings suggest that family members share yet unknown genetic or environmental risk 
factors for VTE.  
 Platelets are known to play an important role in the formation of thrombi. Platelet size, 
measured as MPV, is associated with increased platelet reactivity. Increased levels of MPV 
are found in patients with coronary artery disease [115,116], and MPV has been identified as 
an independent risk factor for myocardial infarction and stroke [117-119]. In the search for 
other potentially shared risk factors for arterial and venous thrombosis, we identified MPV as 
a possible common risk factor (paper IV). To our knowledge, this is the first study showing a 
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relationship between MPV and VTE. However, several factors support the concept of platelet 
reactivity as a risk factor for venous thrombosis. Increased levels of platelet activation 
markers have been reported in patients with PE compared to controls [180]. Furthermore, 
increased levels of P-selectin have been shown in VTE patients [109,181], and higher 
circulating P-selectin was associated with increased risk of recurrent VTE in patients with 
first unprovoked VTE [110]. The identification of MPV as a risk factor for VTE implies that 
platelets might have a more important role in the pathogenesis of venous thrombosis than 
previously assumed.  
Twin studies have shown high heritability estimates for blood cell size and count 
[182,183], and results from the Framingham study suggested that heritable factors play a 
major role in determining platelet aggregation [184]. Moreover, heritability of platelet 
function in families with premature CAD has been reported [185]. Thus, it might be 
speculated that platelet reactivity is a possible common risk factor for both arterial and venous 
thrombosis shared by family members.  
A wide range of other blood constituents such as platelets, erythrocytes, leukocytes 
and inflammatory cytokines, as well as coagulation and fibrinolytic factors are all likely to 
contribute to, or promote, both arterial and venous thrombogenesis [186]. Cellular 
microparticles are small membrane vesicles that are released from cells upon activation or 
apoptosis. Microparticles are considered to constitute the main reservoir of blood-borne tissue 
factor [187], and circulating microparticles provide an additional procoagulant phospholipid 
surface enabling the assembly of the clotting enzyme complexes and thrombin generation 
[188]. Increased levels of circulating microparticles have been reported in cardiovascular 
diseases such as acute coronary syndrome and stroke [189], and in young survivors of MI 
[190]. Moreover, elevated levels of endothelial microparticles and platelet-leukocyte 
conjugates have been reported in VTE patients during the acute phase compared to healthy 
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controls [109], and platelet derived microparticles were increased in subjects with PE [180]. 
However, in a case-control study of 116 cases with recurrent VTE, there were no association 
between circulating microparticles and VTE [191]. Limited data exist on the possible relation 
between endothelial dysfunction and venous thrombosis. A 1:1 case-control study in 28 cases 
and controls reported higher levels of plasma von Willebrand factor and impaired endothelial 
dysfunction, assessed by flow mediated dilation, in subjects with unprovoked VTE [181].  
Factors that influence blood viscosity and blood flow, such as hematocrit, may also 
contribute to risk of thrombosis. Hematocrit levels above the normal population range, such as 
in primary or secondary polycythemia, are associated with increased risk of both arterial and 
venous thrombosis [192,193]. High hematocrit has shown significant association with 
coronary heart disease in some studies of general populations [194], whereas the potential 
relation to risk of VTE has not been extensively examined in general populations.  
In the past few years, results of structural and functional studies have supported a role 
of inflammation in both arterial and venous thrombosis [195]. However, in the LITE-study 
there were no association between VTE and inflammation markers such as CRP and 
leukocytes [152], and mean CRP levels were not related to VTE in the Physicians’ Health 
Study [196]. On the other hand, a few studies suggest that cytokines and chemokines are 
involved in the pathogenesis of VTE. In a population based case-control study with 474 VTE-
patients and 474 healthy controls, elevated levels of interleukin-8 (IL-8) was associated with 
increased risk of VTE [197], and TNF-alpha, IL-6 and IL-8 levels was found to be 
determinants of the risk of VTE [198]. Further prospective studies are required to elucidate 
the role of cellular components and various inflammation markers as common risk factors for 




In our prospective population-based study we found that increasing age, BMI and family 
history of MI were associated with increased risk of VTE. Other traditional cardiovascular 
risk factors such as blood pressure, serum lipid levels including total cholesterol, HDL-
cholesterol and triglycerides, self-reported diabetes and smoking showed no association with 
VTE. The identification of family history of MI as an independent risk factor for VTE 
provides further evidence to the concept of a link between arterial and venous thrombosis. 
Traditional cardiovascular risk factors did not seem to be underlying determinants for this 
association, suggesting that family members share yet unknown genetic or environmental risk 
factors.  
 The metabolic syndrome was associated with increased risk of VTE in our study. 
When analysing the individual components of the syndrome, abdominal obesity was the only 
risk factor independently associated with VTE. Impaired glucose tolerance, hypertension, 
high levels of triglycerides and low HDL-cholesterol showed no association with VTE. 
Furthermore, our results revealed that abdominal obesity was essential for the observed 
association between the metabolic syndrome and VTE.  
 Low HDL-cholesterol was not associated with VTE in our study. In contrast, high 
levels of HDL-cholesterol were apparently associated with increased risk of unprovoked VTE 
in women. Our findings challenge the suggested concept that high HDL-cholesterol protects 
against venous thrombosis. Further studies are needed to determine whether the apparent 
increased risk of unprovoked VTE by HDL-cholesterol in women is a direct effect of HDL or 
due to unrecognized confounders. 
 Increasing levels of MPV was associated with risk of VTE, especially those of 
unprovoked origin. Platelet count showed no association with neither total nor unprovoked 
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VTE. The findings of this study support the concept that platelet reactivity is important in the 
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